Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People with skin squamous cell carcinoma (a type of skin cancer) caused by UV exposure, at an early to advanced stage (Stage I to IVa), where treatment would require extensive or disfiguring surgery
• People with either advanced-stage skin squamous cell carcinoma (Stage III–IVa) or multiple early-stage tumours (Stage I–II) in more than one location
• People whose tumour is located on the lip, ear, face, scalp, neck, eyelid, or other body areas outside the head and neck region (excluding the vulva, anus, or penis)
• People who are well enough to carry out daily activities, as measured by a standard health scale (WHO performance status of 0–2)
• People whose cancer is being treated with curative intent through standard surgery, with or without radiotherapy
• People whose blood test results meet certain minimum safety levels for blood cells, kidney function, and liver function (confirm specific values with trial site)
• Women who could become pregnant must use an appropriate method of contraception during the trial and for a set period after the last dose of the study medication
• Women who could become pregnant must have a negative pregnancy test before starting treatment
• People who are able to understand Dutch study information and are willing to follow the study schedule and requirements

Who may not be able to join:

• People whose skin cancer has spread to distant parts of the body (Stage IVb)
• People whose squamous cell carcinoma is located on a mucosal surface, such as the anus, vulva, penis, or the inner (mucosal) part of the lip
• People whose standard treatment plan involves radiotherapy alone (including brachytherapy) as the main treatment
• People whose cancer has developed in an area of the body that has previously been treated with radiation
• People who have already received systemic therapy or immunotherapy for this condition
• People with active HIV infection or AIDS
• People who test positive for hepatitis B or hepatitis C
• People with an active autoimmune disease or a documented history of autoimmune disease (some exceptions may apply, such as vitiligo, mild psoriasis not requiring systemic treatment, or stable thyroid conditions — confirm with trial site)
• People with other medical conditions that, in the treating doctor's opinion, could make the study drug unsafe or difficult to evaluate
• People who require immunosuppressive medications or high-dose steroid treatments (low-dose steroids up to 5 mg of prednisone per day may be permitted — confirm with trial site)
• People who are pregnant or breastfeeding
• People with a known allergy to the study drug or its components, or a history of severe allergic reactions to similar medications (monoclonal antibodies)
• People who have taken another experimental drug within 30 days before starting this trial, or within a specific timeframe based on how long that drug remains active in the body

Important: Always verify eligibility with the trial site directly before applying.